Do you want to read an article? Please log in or register.
COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?
COPD
RECOMMENDED
Related content
COPD
Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD)
Respir Res.
Chalmers JD, Poole C, Webster S, Tebboth A, Dickinson S, Gayle A
doi: 10.1186/s12931-018-0767-2.
RECOMMENDED
COPD
Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial
JAMA.
Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D
doi: 10.1001/jama.2018.14432.
RECOMMENDED
COPD
Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial
Lancet Respir Med.
Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, Eklöf J, Holm FS, Armbruster K, Sivapalan P, Mosbech C, Ali AKM, Seersholm N, Wilcke JT, Brøndum E, Sonne TP, Rønholt F, Andreassen HF, Ulrik CS, Vestbo J, Jensen JS
doi: 10.1016/
RECOMMENDED
COPD
High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Greulich T, Tüffers J, Mager S, Eder A, Maxheim M, Alter P, Schmeck B, Vogelmeier CF
doi: 10.1186/s12931-020-01365-5.
COMMENTED
Feasibility, acceptability and effectiveness of integrated care for COPD patients: a mixed methods evaluation of a pilot community-based programme
Swiss Med Wkly.
Carron T, Bridevaux PO, Lörvall K, Parmentier R, Moix JB, Beytrison V, Pernet R, Rey C, Roberfroid PY, Chhajed PN, Dieterle T, Joos Zellweger L, Kohler M, Maier S, Miedinger D, Thurnheer R, Urwyler P, Tschopp JM, Zuercher E, Leuppi JD, Burnand B, Peytremann-Bridevaux I
doi: 10.4414/smw.2017.14567.
RECOMMENDED
COPD
Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA
doi: 10.1186/s12931-020-01482-1.
COMMENTED
COPD
Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Alexander Turk, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Magnussen H, Lucas S, Lapperre T, Quint JK, Dandurand RJ, Roche N, Papi A, Price D, Miravitlles M, Respiratory Effectiveness Group (REG).
doi: 10.1186/s12931-021-01615-0
RECOMMENDED
COPD
Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study
Lancet Respir Med.
Suissa S, Dell'Aniello S, Ernst P
doi: 10.1016/S2213-
RECOMMENDED
Asthma
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G
doi: 10.1016/S2213-2600(19)30372-8.